Targeted deletion of Interleukin-3 results in asthma exacerbations

Kölle J, Zimmermann T, Kiefer A, Rieker R, Xepapadaki P, Zundler S, Papadopoulos NG, Finotto S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

iScience Elsevier

Book Volume: 25

Article Number: 104440

Journal Issue: 6

DOI: 10.1016/j.isci.2022.104440

Abstract

The cytokine interleukin-3 (IL-3) acts on early hematopoietic precursor cells. In humans, Treg cells secrete IL-3 and repress inflammatory cells except for basophils. The present study aims to elucidate the contribution of IL-3 in the development and the course of allergic asthma. We therefore analyzed the secretion of IL-3 in PBMCs and total blood cells in two cohorts of pre-school children with and without asthma. In a murine model of allergic asthma, we analyzed the phenotype of IL-3^−/− mice compared to wild-type mice. PBMCs from asthmatic children showed increased IL-3 secretion, which directly correlated with improved lung function. IL-3^−/− asthmatic mice showed increased asthmatic traits. Moreover, IL-3-deficient mice had a defect in T regulatory cells in the lung. In conclusion, IL-3 downregulation was found associated with more severe allergic asthma in pre-school children. Consistently, targeting IL-3 resulted in an induced pathophysiological response in a murine model of allergic asthma.

Authors with CRIS profile

Julia Kölle Department of Molecular Pneumology Theodor Zimmermann Medizinische Fakultät Ralf Rieker Institute of Pathology Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Susetta Neurath-Finotto Department of Molecular Pneumology

Involved external institutions

National and Kapodistrian University of Athens

Greece (GR)

How to cite

APA:

Kölle, J., Zimmermann, T., Kiefer, A., Rieker, R., Xepapadaki, P., Zundler, S.,... Finotto, S. (2022). Targeted deletion of Interleukin-3 results in asthma exacerbations. iScience, 25(6). https://doi.org/10.1016/j.isci.2022.104440

MLA:

Kölle, Julia, et al. "Targeted deletion of Interleukin-3 results in asthma exacerbations." iScience 25.6 (2022).

BibTeX: Download